Next Article in Journal
PEGylated Adenoviruses: From Mice to Monkeys
Next Article in Special Issue
Cross-Reactive Human IgM-Derived Monoclonal Antibodies that Bind to HIV-1 Envelope Glycoproteins
Previous Article in Journal
RNA Replicons - A New Approach for Influenza Virus Immunoprophylaxis
Previous Article in Special Issue
The Development of an AIDS Mucosal Vaccine
Review

Heterologous Prime-Boost HIV-1 Vaccination Regimens in Pre-Clinical and Clinical Trials

1
Department of Immunology, St. Jude Children's Research Hospital, 262 Danny Thomas Place, Memphis, TN, USA
2
Department of Infectious Diseases, St. Jude Children's Research Hospital, 262 Danny Thomas Place, Memphis, TN, USA
3
Early Development, Novartis Vaccines and Diagnostics, 350 Mass Ave. Cambridge, MA 02139, USA
4
Department of Therapeutics, Production and Quality, St. Jude Children's Research Hospital, 262 Danny Thomas Place, Memphis, TN, USA
5
Department of Pediatrics, University of Tennessee, Memphis, TN 38163, USA
6
Department of Pathology, University of Tennessee, Memphis, TN 38163, USA
*
Author to whom correspondence should be addressed.
Viruses 2010, 2(2), 435-467; https://doi.org/10.3390/v2020435
Received: 30 September 2009 / Revised: 12 January 2010 / Accepted: 22 January 2010 / Published: 1 February 2010
(This article belongs to the Special Issue AIDS Vaccine)
Currently, there are more than 30 million people infected with HIV-1 and thousands more are infected each day. Vaccination is the single most effective mechanism for prevention of viral disease, and after more than 25 years of research, one vaccine has shown somewhat encouraging results in an advanced clinical efficacy trial. A modified intent-to-treat analysis of trial results showed that infection was approximately 30% lower in the vaccine group compared to the placebo group. The vaccine was administered using a heterologous prime-boost regimen in which both target antigens and delivery vehicles were changed during the course of inoculations. Here we examine the complexity of heterologous prime-boost immunizations. We show that the use of different delivery vehicles in prime and boost inoculations can help to avert the inhibitory effects caused by vector-specific immune responses. We also show that the introduction of new antigens into boost inoculations can be advantageous, demonstrating that the effect of ‘original antigenic sin’ is not absolute. Pre-clinical and clinical studies are reviewed, including our own work with a three-vector vaccination regimen using recombinant DNA, virus (Sendai virus or vaccinia virus) and protein. Promising preliminary results suggest that the heterologous prime-boost strategy may possibly provide a foundation for the future prevention of HIV-1 infections in humans. View Full-Text
Keywords: HIV-1; prime-boost; heterologous; Sendai virus; clinical trials HIV-1; prime-boost; heterologous; Sendai virus; clinical trials
Show Figures

Figure 1

MDPI and ACS Style

Brown, S.A.; Surman, S.L.; Sealy, R.; Jones, B.G.; Slobod, K.S.; Branum, K.; Lockey, T.D.; Howlett, N.; Freiden, P.; Flynn, P.; Hurwitz, J.L. Heterologous Prime-Boost HIV-1 Vaccination Regimens in Pre-Clinical and Clinical Trials. Viruses 2010, 2, 435-467. https://doi.org/10.3390/v2020435

AMA Style

Brown SA, Surman SL, Sealy R, Jones BG, Slobod KS, Branum K, Lockey TD, Howlett N, Freiden P, Flynn P, Hurwitz JL. Heterologous Prime-Boost HIV-1 Vaccination Regimens in Pre-Clinical and Clinical Trials. Viruses. 2010; 2(2):435-467. https://doi.org/10.3390/v2020435

Chicago/Turabian Style

Brown, Scott A.; Surman, Sherri L.; Sealy, Robert; Jones, Bart G.; Slobod, Karen S.; Branum, Kristen; Lockey, Timothy D.; Howlett, Nanna; Freiden, Pamela; Flynn, Patricia; Hurwitz, Julia L. 2010. "Heterologous Prime-Boost HIV-1 Vaccination Regimens in Pre-Clinical and Clinical Trials" Viruses 2, no. 2: 435-467. https://doi.org/10.3390/v2020435

Find Other Styles

Article Access Map by Country/Region

1
Only visits after 24 November 2015 are recorded.
Search more from Scilit
 
Search
Back to TopTop